Product Images Clopidogrel
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Clopidogrel NDC 54458-888 by International Laboratories, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Clopidogrel Chemical Structure - clopidogrel 1
Figure 8 - clopidogrel 10
EAE - clopidogrel 11
This is a description of a medication package for Clopidogrel Tablets with Noc 5088810. The package contains 4 tablets of Clopidogrel with 75 mg of the active ingredient. The medication is stored in a child-resistant packaging that also includes a medication tracking card that can be pressed and pulled to open. The package has additional warning labels and instructions for use and storage. The package is sold by Walmart.*
CLOPIDOGREL TABLETS USP 75 MG BOTTLE LABEL - clopidogrel 12
Clopidogrel is a prescription drug available in tablet form. Each film-coated tablet contains 97.875 mg of clopidogrel bisulfate USP equivalent to 75 mg of clopidogrel base. It is important to read the medication guide before use. The dosage information is included in the package insert. The bottle should be kept out of reach of children and should not be used if the safety seal under the cap is broken. The package features a child-resistant cap that should be tightly closed after use. The tablets should be stored in a controlled room temperature between 20°C to 25°C (68°F to 77°F). The product is manufactured by International Laboratories, LLC located in St. Petersburg, FL.*
Figure 1 - clopidogrel 2
Figure 2 - clopidogrel 3
This appears to be a chart showing the cumulative event rate of cardiovascular death, myocardial infarction, and stroke for patients using a placebo with aspirin and those using clopidogrel with aspirin, over a period of 9 months of follow-up. The percentage for each category is not clear due to the quality of the text. Other standard therapies were reportedly used as well.*
Figure3 - clopidogrel 4
Figure3_part2 - clopidogrel 5
Figure 4 - clopidogrel 6
The text seems to be presenting data about the effectiveness of a drug called Clopidogrel in reducing the risk of death in a study. The study involved a placebo group and a group of patients who received Clopidogrel. The percentage of deaths was lower in the Clopidogrel group (7.5%) compared to the placebo group (8.1%). The data also suggests that there was a 7% proportional risk reduction associated with the use of Clopidogrel. The study tracked patients for up to 28 days from randomization.*
Figure 5 - clopidogrel 7
The text describes the results of a study comparing the effectiveness of Placebo and Clopidogrel in reducing the risk of death, reinfarction or stroke before the discharge of a patient, within 28 days of randomization. Both groups had a similar number of events, with 10.1% in the Placebo group and 9.2% in the Clopidogrel group. However, the study found a proportional risk reduction of 9% to 9% in Clopidogrel compared to Placebo, which was statistically significant (p=0.002). The text also shows a graph of Days since randomization.*
Figure 6 - clopidogrel 8
Figure 7 - clopidogrel 9
The text shows a graph representing the cumulative event rate in percentages for fatal or non-fatal vascular events, comparing the drugs Aspirin and Clopidogrel. The months of follow-up are also displayed on the graph. The significance level is represented by "P=0.045".*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.